Journal
NANOMEDICINE
Volume 5, Issue 7, Pages 1065-1074Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.10.78
Keywords
antiangiogenics; combination therapy; K/BxN arthritis model; nanotherapeutics; rheumatoid arthritis
Funding
- NIH [AR056468, CA119342, HL073646, NS059302, HL094470]
Ask authors/readers for more resources
Aim: This study examines the effect of combining the antiangiogenic effect of alpha(v)beta(3)-targeted fumagillin nanoparticles with the conventional antirheumatic drug methotrexate for the treatment of inflammatory arthritis. Method: Arthritis was induced in mice by K/BxN serum transfer, and disease activity was monitored by clinical score and change in ankle thickness. Groups of mice received nanoparticles or methotrexate as single therapy or nanoparticles and methotrexate as combination therapy. Results: We found that animals treated with a pulse dose of fumagillin nanoparticles followed by methotrexate had significantly improved and sustained clinical response compared with those treated with either agent alone. Histological analysis confirmed a significant decrease in inflammatory cell influx, bone erosions, cartilage damage and angiogenesis with the combination therapy. Conclusion: Analysis of plasma cytokine levels suggests that fumagillin nanoparticles enhanced the systemic anti-inflammatory effects of methotrexate. Antiangiogenic nanotherapy may represent a promising approach for the treatment of inflammatory arthritis when combined with a conventional antirheumatic drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available